| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comprehensive molecular portraits of human breast tumours.
|
Nature
|
2012
|
47.39
|
|
2
|
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
|
Breast Cancer Res
|
2009
|
5.20
|
|
3
|
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
|
J Clin Oncol
|
2009
|
4.69
|
|
4
|
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
|
Breast Cancer Res
|
2008
|
3.80
|
|
5
|
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
|
J Clin Oncol
|
2009
|
3.56
|
|
6
|
Palbociclib and Letrozole in Advanced Breast Cancer.
|
N Engl J Med
|
2016
|
2.37
|
|
7
|
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).
|
Lancet Oncol
|
2012
|
2.16
|
|
8
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
|
Lancet Oncol
|
2016
|
1.41
|
|
9
|
Sample size and optimal design for logistic regression with binary interaction.
|
Stat Med
|
2008
|
1.38
|
|
10
|
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
|
Clin Cancer Res
|
2012
|
1.03
|
|
11
|
Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.
|
Oncologist
|
2014
|
0.92
|
|
12
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
|
Breast Cancer Res Treat
|
2013
|
0.81
|
|
13
|
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
|
Cancer Treat Rev
|
2015
|
0.81
|
|
14
|
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
|
Oncotarget
|
2016
|
0.75
|